NASDAQ: ALZN - Alzamend Neuro, Inc.

Yield per half year: -69.7%
Dividend yield: 0.00%
Sector: Healthcare

Share chart Alzamend Neuro, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About Alzamend Neuro, Inc.

Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders.

more details
The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2021-06-15
ISIN US02262M3088
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.alzamend.com
Цена ао 0.9952
Change price per day: -3.23% (1.24)
Change price per week: +8.11% (1.11)
Change price per month: -5.14% (1.265)
Change price per 3 month: -32.2% (1.77)
Change price per half year: -69.7% (3.96)
Change price per year: +34.83% (0.89)
Change price per 3 year: -42.86% (2.1)
Change price per 5 year: 0% (1.2)
Change price per 10 year: 0% (1.2)
Change price per year to date: -19.46% (1.49)
All parameters

Underestimation

Title Value Grade
P/S 0 0
P/BV -1.85 0
P/E 0 0
EV/EBITDA -0.4789 0
Total: 2.5

Efficiency

Title Value Grade
ROA, % -303.88 0
ROE, % -4408.31 0
Total: 1.67

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.0304 10
Total: 8.6

Growth impulse

Title Value Grade
Yield Revenue, % 0 0
Yield Ebitda, % 124.7 10
Yield EPS, % 29906.76 10
Total: 8
More

Institutions Volume Share, %
Truist Financial Corp 154327 2.25
Vanguard Group Inc 78545 1.14
Geode Capital Management, LLC 52397 0.76
Blackrock Inc. 39740 0.58
HRT Financial LP 16806 0.24
RFG Advisory, LLC 16666 0.24
Renaissance Technologies, LLC 10190 0.15
Tower Research Capital LLC (TRC) 3316 0.05
UBS Group AG 1909 0.03
HARBOR INVESTMENT ADVISORY, LLC 200 0



Head Job title Payment Year of birth
Mr. Stephan Jackman CEO & Director 434.24k 1976 (49 years)
Mr. David J. Katzoff Chief Financial Officer 116.67k 1962 (63 years)
Mr. Henry C. W. Nisser Esq. Executive VP, General Counsel & Director 50k 1969 (56 years)
Mr. Milton Charles Ault III Founder & Vice Chairman N/A 1970 (55 years)

Address: United States, Atlanta. GA, 3480 Peachtree Road NE - open in Google maps, open in Yandex maps
Website: https://www.alzamend.com